Is There More Room for 3SBio After Its 431% Surge and Recent Earnings Release?

Simply Wall St.

Sep 24

So, you are sizing up what to do with 3SBio stock, a company that has been turning heads with its dramatic long-term rise and seemingly small short-term stumbles. If you have been watching its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569745456"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569745456\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569745456?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-09-24 01:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569745456","market":"hk","top_or_hot":-1,"title":"Is There More Room for 3SBio After Its 431% Surge and Recent Earnings Release?","media":"Simply Wall St.","content":"<div>\n<p>So, you are sizing up what to do with 3SBio stock, a company that has been turning heads with its dramatic long-term rise and seemingly small short-term stumbles. If you have been watching its ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/is-there-more-room-for-3sbio-after-its-431-surge-and-recent\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is There More Room for 3SBio After Its 431% Surge and Recent Earnings Release?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs There More Room for 3SBio After Its 431% Surge and Recent Earnings Release?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-24 01:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/is-there-more-room-for-3sbio-after-its-431-surge-and-recent><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, you are sizing up what to do with 3SBio stock, a company that has been turning heads with its dramatic long-term rise and seemingly small short-term stumbles. If you have been watching its ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/is-there-more-room-for-3sbio-after-its-431-surge-and-recent\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/is-there-more-room-for-3sbio-after-its-431-surge-and-recent","article_id":"2569745456","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/is-there-more-room-for-3sbio-after-its-431-surge-and-recent","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2569745456","pubTimestamp":1758647282,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"So, you are sizing up what to do with 3SBio stock, a company that has been turning heads with its dramatic long-term rise and seemingly small short-term stumbles. If you have been watching its performance over the last year, you have seen an astonishing 431.0% gain and an even greater 492.7% climb over the past three years. Yes, the last week saw a dip of -2.8%, and the past month is down just -0.5%, but zoom out a bit and 3SBio’s chart tells a much bigger story. These returns suggest...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK1161":"生物科技","BK1593":"医美概念股","01530":"三生制药","BK1583":"高瓴概念"},"translate_title":"在飙升431%和最近发布财报后，三生制药还有更大的空间吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":0.9,"DCF":1},"content_text":"So, you are sizing up what to do with 3SBio stock, a company that has been turning heads with its dramatic long-term rise and seemingly small short-term stumbles. If you have been watching its performance over the last year, you have seen an astonishing 431.0% gain and an even greater 492.7% climb over the past three years. Yes, the last week saw a dip of -2.8%, and the past month is down just -0.5%, but zoom out a bit and 3SBio’s chart tells a much bigger story. These returns suggest investors already see growth potential, even after accounting for short bouts of volatility, and some of that optimism can be traced to shifting perceptions about the sector and recent activity in broader markets. But high returns do not always mean a stock is expensive. In fact, 3SBio posts a value score of 4, meaning it appears undervalued in 4 out of 6 key checks analysts typically look at. That score puts 3SBio right at the center of the debate: is this monster run already priced in, or is there still upside? Let’s break down how the major valuation methods score this company, and then explore an even smarter way to judge if it is truly undervalued or not. 3SBio delivered 431.0% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementApproach 1: 3SBio Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow (DCF) valuation estimates what a company is worth by projecting its future cash flows and then discounting them back to today’s value. For 3SBio, analysts start with its latest twelve-month Free Cash Flow of approximately CN¥2.24 billion and project these out over the next decade. The company’s cash flows are forecast to grow steadily, reaching an estimated CN¥6.58 billion by 2035. Projections through 2029, which are more reliable as they rely on direct analyst forecasts, anticipate Free Cash Flow rising to CN¥4.53 billion. After that, figures are extrapolated based on industry trends and 3SBio’s historical growth rates. Using the two-stage Free Cash Flow to Equity model, these future flows are discounted back to reflect their value today. The DCF model values 3SBio shares at CN¥52.76, which is 41.4% higher than the current trading price. In other words, the stock is considered to be significantly undervalued on this basis, suggesting that if these forecasts play out, there is substantial room for upside. Result: UNDERVALUED Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for 3SBio. 1530 Discounted Cash Flow as at Sep 2025 Our Discounted Cash Flow (DCF) analysis suggests 3SBio is undervalued by 41.4%. Track this in your watchlist or portfolio, or discover more undervalued stocks. Approach 2: 3SBio Price vs Earnings (PE) The Price-to-Earnings (PE) ratio is a popular yardstick for valuing profitable companies like 3SBio, as it reflects how much investors are willing to pay for each dollar of the company's earnings. Because earnings capture both profitability and future growth expectations, the PE ratio helps put a company’s price in context. In general, higher growth and lower risk can justify a higher PE, while slow-growing or riskier businesses typically trade at a discount. 3SBio's current PE ratio stands at 28.7x. This figure is just below the Biotechs industry average of 29.2x, and notably, it is well below the average of its direct peers at 53.1x. However, these direct comparisons can miss the bigger picture. To address this, Simply Wall St calculates a “Fair Ratio,” which is a PE multiple that factors in 3SBio’s specific earnings growth prospects, profit margins, scale, and risk profile, as well as broader industry trends. In 3SBio’s case, the Fair Ratio is calculated at 21.8x. Because the Fair Ratio tunes out market noise and isolates the company’s underlying fundamentals, it often delivers a clearer verdict on valuation than peer and industry comparisons alone. With 3SBio’s current PE of 28.7x sitting moderately above its Fair Ratio, this suggests the stock is leaning toward being slightly overvalued based on earnings. The premium might reflect market optimism or anticipated growth, but strictly on this basis, it is trading above what would normally be warranted for its profile. Result: OVERVALUED SEHK:1530 PE Ratio as at Sep 2025 PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your 3SBio Narrative Earlier we mentioned that there is an even better way to understand valuation, so let’s introduce you to Narratives. Narratives make investing simpler by connecting your personal story about a company to real financial forecasts and a calculated fair value. Rather than just relying on static ratios or analyst models, Narratives empower you to define your own perspective, set assumptions about future revenue, earnings, and margins, and instantly see what those beliefs mean for 3SBio’s value. This approach provides a direct link between your outlook for a business and actionable insights. It gives you a Fair Value you can compare to today’s price to help decide when to buy or sell. The platform on Simply Wall St, which is used by millions of investors, makes Narratives accessible and easy to experiment with in the Community page. Best of all, as news breaks or earnings are released, your Narrative updates dynamically so your assumptions and fair value always stay relevant. For example, some 3SBio Narratives in the Community see a fair value nearly double the current price, while others take a more cautious view. Do you think there's more to the story for 3SBio? Create your own Narrative to let the Community know! SEHK:1530 Earnings & Revenue History as at Sep 2025  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if 3SBio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}